Relationship Between Everolimus Blood Concentration Assessed Using the Innofluor Certican Fluorescence Polarization Immunoassay and the Architect i System Sirolimus Chemiluminescent Microparticle Immunoassay

Transplantation Proceedings

Volumn 42, Issue 5, 2010, Pages 1867-1869

  Coentrao L ^a,b   Carvalho, C ^b   Sampaio, S ^b   Oliveira, J G ^b   Pestana, M I ^b  

^a University of Porto   (Portugal)

^b HOSPITAL DE SÃO JOÃO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN;

ADULT; ARTICLE; CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY; CROSS REACTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MONITORING; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; FOLLOW UP; HUMAN; IMMUNOASSAY; IMMUNOSUPPRESSIVE TREATMENT; INTERMETHOD COMPARISON; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; TREATMENT OUTCOME;

FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LUMINESCENCE; MALE; MIDDLE AGED; REGRESSION ANALYSIS; SIROLIMUS;

EID: 77953667783     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2010.01.059     Document Type: Article

References (7)

1. Kirchner G.I., Meier-Wiedenbach I., and Manns M.P. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 43 (2004) 83
2. Mahalati K., and Kahan B.D. Clinical pharmacokinetics of sirolimus. Clin Pharmacokinet 40 (2001) 573
3. Mabasa V.H., and Ensom M.H.H. The role of therapeutic monitoring of everolimus in solid organ transplantation. Ther Drug Monit 27 (2005) 666
4. Pieri M., Miraglia N., Gentile A., et al. Quantification of sirolimus and everolimus by immunoassay techniques: test specificity and cross-reactivity evaluation. Int J Immunopathol Pharmacol 21 (2008) 585
5. Bouzas L., and Tutor J.C. Determination of everolimus in whole blood using the Abbott IMx sirolimus microparticle enzyme immunoassay. Clin Biochem 40 (2007) 132
6. Pascual J., Boletis J.N., and Campistol J.M. Everolimus (Certican) in renal transplant: a review of clinical trial data, current usage and future directions. Transplant Rev 20 (2006) 1
7. Ruiz J.C., Sanchez-Fructuoso A., Rodrigo E., et al. Conversion to everolimus in kidney transplant recipients: a safe and simple procedure. Transplant Proc 38 (2006) 2424